Business Context and Reporting Period
This Form 8-K, dated November 12, 2025, reports on Qualigen Therapeutics, Inc. (filing as Qualigen Therapeutics, Inc. but transitioning to AIxCrypto Holdings, Inc.). The filing covers events occurring between November 12 and November 16, 2025, including a shareholder meeting and a corporate name change.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate governance and capital structure changes rather than operational financial performance.
Material Changes
- Corporate Name Change: The company filed a Certificate of Amendment to change its name from "Qualigen Therapeutics, Inc." to "AIxCrypto Holdings, Inc." effective November 14, 2025.
- Trading Symbol Change: Common stock will cease trading under the ticker "QLGN" and begin trading under "AIXC" on the Nasdaq Capital Market.
- Capital Raise Approval: Shareholders approved a private placement transaction involving the issuance of 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock.
- Equity Plan Approval: Shareholders approved the 2025 Equity Incentive Plan.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard implications of a name change and capital restructuring. The name change was effected without a shareholder vote as permitted by Delaware law and does not affect shareholder rights.
Investor Verification Checklist
- Verify the effective date of the ticker symbol change from QLGN to AIXC on Nasdaq.
- Review the Subscription Agreement dated September 19, 2025, for details on the private placement terms.
- Confirm the terms of the Series B Convertible Preferred Stock and the 19.99% share exchange cap.
- Examine the 2025 Equity Incentive Plan details for potential dilution impacts.
- Check the press release dated November 16, 2025 (Exhibit 99.1) for additional business updates regarding the pivot to AIxCrypto.